PR Newswire Clinical TrialsOriginal article
JACC: Clinical Electrophysiology publie les résultats à 12 mois du premier essai Field PULSE chez l'humain de Field Medical : 94,2 % de durabilité de l'isolement des veines pulmonaires, par veine, grâce à une forme d'onde optimisée
Data ReadoutpositiveFieldForce PFA SystemPositive
AI Analysis
Summary
Field Medical announced 12-month data from its first human Field PULSE trial demonstrating 94.2% durability of pulmonary vein isolation per vein using optimized waveform technology with the FieldForce PFA system. The late-breaking data, presented at HRX conference, advances the company's instantaneous ablation protocol for pulsed field ablation treatment.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
12-month durability of pulmonary vein isolation at 94.2% per vein with optimized waveform in first human Field PULSE trial
Importance:6/10
Sentiment:
0.80
pulmonary vein isolationatrial fibrillationablationpulsed field ablationclinical trial12-month data
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 20, 2026 7:34 PM